CDC NEWS


powered by Surfing Waves


Latest News


Pfizer Asks F.D.A. to Authorize Its Covid-19 Vaccine for Children 5 to 11


07 Oct 2021

WASHINGTON — Pfizer and BioNTech said on Thursday morning that they had asked federal regulators to authorize emergency use of their coronavirus vaccine for children ages 5 to 11, a move that could help protect more than 28 million people in the United States.


The Latest on COVID-19 Boosters


28 Sep 2021

More than 180 million Americans, including more than 80 percent of people over age 65, are fully vaccinated against the SARS-CoV-2 virus responsible for COVID-19. There’s no question that full vaccination is the best way to protect yourself against this devastating virus and reduce your chances of developing severe or long-lasting illness if you do get sick. But, to stay ahead of this terrible virus, important questions do remain. A big one right now is: How soon will booster shots be needed and for whom?


FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations


23 Sep 2021

Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to allow for use of a single booster dose, to be administered at least six months after completion of the primary series in: individuals 65 years of age and older; individuals 18 through 64 years of age at high risk of severe COVID-19; and individuals 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19 including severe COVID-19


The Most Common COVID-19 Booster Shot Questions, Answered


23 Sep 2021

The Food and Drug Administration has authorized Pfizer COVID-19 booster shots for people over the age of 65 and other at-risk Americans. The agency’s decision was the latest twist in the ongoing debate about when coronavirus booster shots would be necessary — and for whom.


Covid Live Updates: Extra Dose of J. & J. Vaccine Raises Protection, Company Says


21 Sep 2021

In a clinical trial, researchers found that two doses of the vaccine delivered 94 percent efficacy against mild to severe Covid-19.




Articles


Association of Major Depressive Symptoms With Endorsement of COVID-19 Vaccine Misinformation Among US Adults


21 Jan 2022

Key Points Question Are major depressive symptoms associated with increased risk of believing common misinformation about COVID-19 vaccines among US adults? Findings In this survey study including 15 464 US adults, people with moderate or greater major depressive symptoms on an initial survey were more likely to endorse at least 1 of 4 false statements about COVID-19 vaccines on a subsequent survey, and those who endorsed these statements were half as likely to be vaccinated. Meaning These findings suggest another potential benefit of public health efforts to address depressive symptoms, namely reducing susceptibility to misinformation.




Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves


30 Dec 2021

On November 24, 2021, a SARS-CoV-2 variant of concern, Omicron (B.1.1.529), was identified in South Africa as responsible for a fourth wave of COVID-19.1,2 The high number of spike mutations has raised concerns about its ability to evade vaccine and spread.3,4 We assessed hospitalized patients with a positive SARS-CoV-2 test result during the fourth wave compared with previous waves.




Why Parents Still Hesitate to Vaccinate Their Children Against COVID-19


15 Dec 2021

As of early December, more than 2.3 million children aged 5 to 11 years had developed COVID-19 and 209 had died. Although a vaccine that’s 90.7% effective in preventing the illness was authorized for younger kids in late October, these figures apparently aren’t convincing enough to persuade many parents to vaccinate their children.




Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination


04 Nov 2021

The current surge in infections with the SARS-CoV-2 Delta variant has made it clear to health care workers and the public alike that fully vaccinated people remain at risk for SARS-CoV-2 infections. It is also apparent that breakthrough infections in fully vaccinated people can sometimes be serious. As of October 21, 2021, for example, 35% of the 519 patients hospitalized with COVID-19 in Massachusetts had been fully vaccinated.1 Furthermore, multiple reports have documented that if fully vaccinated individuals do become infected, their viral loads may be as high as the levels seen in unvaccinated individuals.




Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans


06 Oct 2021

Question What was the COVID-19 vaccination coverage and estimated mRNA COVID-19 vaccine effectiveness (VE) among US veterans in the first 3 months following vaccine rollout? Findings In this case-control study including 6 647 733 veterans, 23% of veterans received at least 1 COVID-19 vaccination during the first 3 months of vaccine rollout. VE against infection was estimated to be 95% for full vaccination; estimated VE against COVID-19-related hospitalization was 91%, and there were no COVID-19–related deaths among fully vaccinated veterans. Meaning These findings suggest that early vaccination rollout for veterans was efficient, and estimated VE was high for this diverse US population.




Enroll for Free